VRIO Analysis of E-Therapeutics Plc
Posted by Zachary Edwards on Mar-22-2018
The VRIO Analysis of E-Therapeutics Plc will look at each of its internal resources one by one to assess whether these provide sustained competitive advantage. The E-Therapeutics Plc VRIO Analysis also mentions at each stage whether these resources could be improved to provide a greater competitive advantage. Lastly, the resources analysed are summarised as to whether they offer sustained competitive advantage, has an unused competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage.
Valuable
- The E-Therapeutics Plc VRIO Analysis shows that the financial resources of E-Therapeutics Plc are highly valuable as these help in investing into external opportunities that arise. These also help E-Therapeutics Plc in combating external threats.
- According to the VRIO Analysis of E-Therapeutics Plc, its local food products are a valuable resource as these are highly differentiated. This makes the perceived value for these by customers high. These are also valued more than the competition by customers due to the differentiation in these products.
- The E-Therapeutics Plc VRIO Analysis shows that E-Therapeutics Plc's employees are a valuable resource to the firm. A significant portion of the workforce is highly trained, and this leads to more productive output for the organisation. The employees are also loyal, and retention levels for the organisation are high. All of this translates into greater value for the end consumers of E-Therapeutics Plc's products.
- According to the VRIO Analysis of E-Therapeutics Plc, its patents are a valuable resource as these allow the firm to sell its products without competitive interference. This results in greater revenue for E-Therapeutics Plc. These patents also provide E-Therapeutics Plc with licensing revenue when it licenses these patents out to other manufacturers.
- The E-Therapeutics Plc VRIO Analysis shows that E-Therapeutics Plc’s distribution network is a valuable resource. This helps it in reaching out to more and more customers. This ensures greater revenues for E-Therapeutics Plc. It also ensures that promotion activities translate into sales as the products are easily available.
- According to the VRIO Analysis of E-Therapeutics Plc, its cost structure is not a valuable resource. This is because the methods of production lead to greater costs than that of competition, which affects the overall profits of the firm. Therefore, its cost structure is a competitive disadvantage that needs to be worked on.
- The E-Therapeutics Plc VRIO Analysis shows that the research and development at E-Therapeutics Plc is not a valuable resource. This is because research and development are costing more than the benefits it provides in the form of innovation. There have been very few innovative features and breakthrough products in the past few years. Therefore, research and development are a competitive disadvantage for E-Therapeutics Plc. It is recommended that the research and development teams are improved, and costs are cut for these.
Rare
- The financial resources of E-Therapeutics Plc are found to be rare according to the VRIO Analysis of E-Therapeutics Plc. Strong financial resources are only possessed by a few companies in the industry.
- The local food products are found to be not rare as identified by E-Therapeutics Plc VRIO Analysis. These are easily provided in the market by other competitors. This means that competitors can use these resources in the same way as E-Therapeutics Plc and inhibit competitive advantage. This means that the local food products result in competitive parity for E-Therapeutics Plc. As this resource is valuable, E-Therapeutics Plc can still make use of this resource.
- The employees of E-Therapeutics Plc are a rare resource as identified by the VRIO Analysis of E-Therapeutics Plc. These employees are highly trained and skilled, which is not the case with employees in other firms. The better compensation and work environment ensure that these employees do not leave for other firms.
- The patents of E-Therapeutics Plc are a rare resource as identified by the E-Therapeutics Plc VRIO Analysis. These patents are not easily available and are not possessed by competitors. This allows E-Therapeutics Plc to use them without interference from the competition.
- The distribution network of E-Therapeutics Plc is a rare resource as identified by the VRIO Analysis of E-Therapeutics Plc. This is because competitors would require a lot of investment and time to come up with a better distribution network than that of E-Therapeutics Plc. These are also possessed by very few firms in the industry.
Imitable
- The financial resources of E-Therapeutics Plc are costly to imitate as identified by the E-Therapeutics Plc VRIO Analysis. These resources have been acquired by the company through prolonged profits over the years. New entrants and competitors would require similar profits for a long period of time to accumulate these amounts of financial resources.
- The local food products are not that costly to imitate as identified by the VRIO Analysis of E-Therapeutics Plc. These can be acquired by competitors as well if they invest a significant amount in research and development. These also do not require years long experience. Therefore, the local food products by E-Therapeutics Plc provide it with a temporary competitive advantage that competitors can too acquire in the long run.
- The employees of E-Therapeutics Plc are also not costly to imitate as identified by the E-Therapeutics Plc VRIO Analysis. This is because other firms can also train their employees to improve their skills. These companies can also hire employees from E-Therapeutics Plc by offering better compensation packages, work environment, benefits, growth opportunities etc. This makes the employees of E-Therapeutics Plc a resource that provides a temporary competitive advantage. Competition can acquire these in the future.
- The patents of E-Therapeutics Plc are very difficult to imitate as identified by the VRIO Analysis of E-Therapeutics Plc. This is because it is not legally allowed to imitate a patented product. Similar resources to be developed and getting a patent for them is also a costly process.
- The distribution network of E-Therapeutics Plc is also very costly to imitate by competition as identified by the E-Therapeutics Plc VRIO Analysis. This has been developed over the years gradually by E-Therapeutics Plc. Competitors would have to invest a significant amount if they are to imitate a similar distribution system.
Organisation
- The financial resources of E-Therapeutics Plc are organised to capture value as identified by the VRIO Analysis of E-Therapeutics Plc. These resources are used strategically to invest in the right places; making use of opportunities and combatting threats. Therefore, these resources prove to be a source of sustained competitive advantage for E-Therapeutics Plc.
- The Patents of E-Therapeutics Plc are not well organised as identified by the E-Therapeutics Plc VRIO Analysis. This means that the organisation is not using these patents to their full potential. An unused competitive advantage exists that can be changed into a sustainable competitive advantage if E-Therapeutics Plc starts selling patented products before the patents expire.
- The distribution network of E-Therapeutics Plc is organised as identified by the VRIO Analysis of E-Therapeutics Plc. E-Therapeutics Plc uses this network to reach out to its customers by ensuring that products are available on all of its outlets. Therefore, these resources prove to be a source of sustained competitive advantage for E-Therapeutics Plc.
From the VRIO Analysis of E-Therapeutics Plc, it was identified that the financial resources and distribution network provide a sustained competitive advantage. The patents are a source of unused competitive advantage. There exists a temporary competitive advantage for employees. There exists a competitive parity for local food products. Lastly, the cost structure of E-Therapeutics Plc is a competitive disadvantage. Research and Development is also a competitive disadvantage.
Warning! This article is only an example and cannot be used for research or reference purposes. If you need help with something similar, please submit your details here.
Florian Leon
5.0
The work is always completed to a high standard. The confidentiality system is satisfactory.
Thomas Sam
5.0
I’ll be the regular client of this service till the end of course. Good effort in composing the assignment.
Julia Jonathan
5.0
Please use this website because it's not a scam. The essay was completed with a quality structure like intro, body and conclusion. Very real people! Thanks a lot!
Sarah Jeremy
5.0
These guys really rock. I got what I wanted. Thank you very much!
Next Articles
- Evgen Pharma Plc Vrio Analysis
- Faron Pharmaceuticals Oy Vrio Analysis
- Futura Medical Plc Vrio Analysis
- Genedrive Plc Vrio Analysis
- Genus Plc Vrio Analysis
- Georgia Healthcare Group Plc Vrio Analysis
- Gunsynd Plc Vrio Analysis
- Hikma Pharmaceuticals Plc Vrio Analysis
- Horizon Discovery Group Plc Vrio Analysis
- Hutchison China Meditech Limited Vrio Analysis
Previous Articles
- Ergomed Plc Vrio Analysis
- Ekf Diagnostics Holdings Plc Vrio Analysis
- Eden Research Plc Vrio Analysis
- Eco Animal Health Group Plc Vrio Analysis
- Diurnal Group Plc Vrio Analysis
- Deltex Medical Group Plc Vrio Analysis
- Dechra Pharmaceuticals Plc Vrio Analysis
- Creo Medical Group Plc Vrio Analysis
- Convatec Group Plc Vrio Analysis
- Consort Medical Plc Vrio Analysis
Be a great writer or hire a greater one!
Academic writing has no room for errors and mistakes. If you have BIG dreams to score BIG, think out of the box and hire Case48 with BIG enough reputation.
Our Guarantees
Interesting Fact
Most recent surveys suggest that around 76 % students try professional academic writing services at least once in their lifetime!